Oliver Maracic, Investor, shared a post on LinkedIn:
“Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer LGSOC (ENGOT-ov60/GOG-3052/RAMP 201): Dose Intensity and Subgroup Analysis
In KRASm patients,
– ORR was 47% (no prior MEK inhibitor, n=45) vs 33% (prior MEK inhibitor, n=12),
– 53% (no prior bevacizumab, n=34) vs 30% (prior bevacizumab, n=23),
– 49% (1-3 prior therapies, n=35) vs 36% (>3 prior therapies, n=22).
In KRAS wild-type patients,
– ORR was 18% (no prior MEK inhibitor, n=39) vs 15% (prior MEK inhibitor, n=13),
– 25% (no prior bevacizumab, n=20) vs 13% (prior bevacizumab, n=32),
– 21% (1-3 prior therapies, n=28) vs 13% (>3 prior therapies, n=24).”
